NCT03844178

Brief Summary

patients who are candidates of PRK will be recruited in this intrasubject randomized clinical trial. Inclusion criteria are myopia or myopic astigmatism with refractive cylinder. Exclusion criteria were unstable refractive error, age less than 21 years old, corneal opacity, keratoconus, keratoconus suspects, residual corneal stromal thickness less than 350 µm, moderate or severe dry eye disease and any other ocular pathology other than refractive error. Complete eye exam will be performed preoperatively including: uncorrected distance visual acuity (UDVA), best spectacle corrected distance visual acuity (CDVA), cyclorefraction, slit lamp biomicroscopy, Goldmann applannation tonometry, dual scheimpflug tomography (Ziemmer), topography in mesopic condition accompanied by pupilometry and iris registration (Topolyzer Vario, Alcon Laboratories, Inc., Fort Worth, TX), and funduscopy with dilated pupil. Surgical Technique The same surgeon (A.F.) will perform all surgeries. After installation of Tetracaine 1%, periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. In the right eye of each patient PCS compensation will be turned on (PCS-On group) and in the left eye it will be turned off (PCS-Off group). Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA). Selection of which eye to be first ablated will be done randomly. Randomization will be performed based on a computer software by a Biostatistician which produced the first eye to be operated. Static cyclotorsion compensation will be active in all eyes. The ablation profile will be wavefront-optimized in all cases. Postoperative Course Postoperatively, chloramphenicol 0.5% eye drops and betamethasone 0.1% eye drops will be prescribed every 6 hours for 10 days. Thereafter, Fluorometholone 0.1% eye drops every 6 hours for 1 month and every 8 hours for the next month will be given. Follow-up examinations were scheduled at 1, 2, 3, 4, 7 and 15 days and 1, 2, 3, and 6 months postoperatively. After contact lens removal each follow-up examination includes the UDVA, manifest refraction, and IOP measurements as well as a slit lamp biomicroscopy. Corneal imaging with Galilei tomography, CDVA and cyclorefraction will be performed at the final follow-up examination 6 months postoperatively.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
104

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Feb 2019

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 2, 2019

Completed
8 days until next milestone

Study Start

First participant enrolled

February 10, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 18, 2019

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2019

Completed
Last Updated

February 18, 2019

Status Verified

February 1, 2019

Enrollment Period

4 months

First QC Date

February 2, 2019

Last Update Submit

February 13, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Postoperative refractive error

    Snellen chart and subjective refraction

    2 months

Secondary Outcomes (1)

  • Root Mean Square (RMS) of higher order aberration

    6 months

Study Arms (2)

The right eyes with compensation for Pupil centroid shift

ACTIVE COMPARATOR
Procedure: The option for compensation of Pupil centroid shift was ONDrug: installation of Tetracaine 1%Procedure: Photorefractive keratectomy (PRK)

The left eyes without compensation for Pupil centroid shift

ACTIVE COMPARATOR
Procedure: The option for compensation of Pupil centroid shift was OFFDrug: installation of Tetracaine 1%Procedure: Photorefractive keratectomy (PRK)

Interventions

The option for compensation of Pupil centroid shift was ON

The right eyes with compensation for Pupil centroid shift

The option for compensation of Pupil centroid shift was OFF

The left eyes without compensation for Pupil centroid shift

installation of Tetracaine 1%

The left eyes without compensation for Pupil centroid shiftThe right eyes with compensation for Pupil centroid shift

periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA)

The left eyes without compensation for Pupil centroid shiftThe right eyes with compensation for Pupil centroid shift

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • myopia
  • myopic astigmatism

You may not qualify if:

  • unstable refractive error, age less than 21 years old
  • corneal opacity
  • keratoconus, keratoconus suspects
  • residual corneal stromal thickness less than 350 µm
  • moderate or severe dry eye disease
  • any other ocular pathology other than refractive error

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ophthalmic Research Center

Tehran, Iran

RECRUITING

MeSH Terms

Interventions

Photorefractive Keratectomy

Intervention Hierarchy (Ancestors)

Corneal Surgery, LaserLaser TherapyTherapeuticsAblation TechniquesSurgical Procedures, OperativeKeratectomyRefractive Surgical ProceduresOphthalmologic Surgical Procedures

Central Study Contacts

Amir Faramarzi, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of ophthalmic research center

Study Record Dates

First Submitted

February 2, 2019

First Posted

February 18, 2019

Study Start

February 10, 2019

Primary Completion

June 1, 2019

Study Completion

July 1, 2019

Last Updated

February 18, 2019

Record last verified: 2019-02

Locations